Normal view
-
TechCrunch
-
OpenEvidence hits $12B valuation, with new round led by Thrive, DST
The medical info database has doubled in valuation since last raise in October, despite encroachment from model makers.
-
Latest Science News -- ScienceDaily
-
A simple blood test mismatch linked to kidney failure and death
A major global study suggests that a hidden mismatch between two common blood tests could quietly signal serious trouble ahead. When results from creatinine and cystatin C—two markers used to assess kidney health—don’t line up, the risk of kidney failure, heart disease, and even death appears to rise sharply. Researchers found that this gap is especially common among hospitalized and older patients, and that relying on just one test may miss early warning signs.
A simple blood test mismatch linked to kidney failure and death
-
STAT

-
STAT+: OpenEvidence raises $250 million, doubling its valuation
OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding. The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians. Founded in 2022, OpenEvidence
STAT+: OpenEvidence raises $250 million, doubling its valuation
OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding.
The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians.
Founded in 2022, OpenEvidence is one of the most prominent and best-funded companies from a wave of health artificial intelligence companies that emerged since the widespread availability of large language models. Reflecting on the eye-popping fundraising for health AI, a Silicon Valley Bank report released earlier in January raised an eyebrow at the ability of companies like OpenEvidence to deliver on their stratospheric valuations with advertising and software-as-a-service business models. “It won’t be a surprise to see them tap the value of the data they’re already collecting” to offer more services to pharma or other customers, the authors wrote.
Continue to STAT+ to read the full story…


© Adobe
-
(Multiomics OR Omics) AND (Pancreatic)
-
Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability
Clin Transl Oncol. 2026 Jan 21. doi: 10.1007/s12094-025-04214-3. Online ahead of print.ABSTRACTPancreatic cancer (PC), predominantly pancreatic ductal adenocarcinoma, remains one of the most lethal malignancies, largely due to late diagnosis and intrinsic resistance to conventional therapies. In recent years, mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) have emerged as clinically actionable biomarkers in a small but distinct subset of PC, accounting for approxima
Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability
Clin Transl Oncol. 2026 Jan 21. doi: 10.1007/s12094-025-04214-3. Online ahead of print.
ABSTRACT
Pancreatic cancer (PC), predominantly pancreatic ductal adenocarcinoma, remains one of the most lethal malignancies, largely due to late diagnosis and intrinsic resistance to conventional therapies. In recent years, mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) have emerged as clinically actionable biomarkers in a small but distinct subset of PC, accounting for approximately 1-2% of cases. These tumors display unique molecular characteristics, including a high prevalence of wild-type KRAS and TP53, elevated tumor mutational burden, and recurrent kinase fusions, which together confer enhanced immunogenicity and increased sensitivity to immune checkpoint inhibitors (ICIs). In addition to their therapeutic relevance, dMMR/MSI-H status has important diagnostic implications for the identification of Lynch syndrome-associated pancreatic cancers, informing genetic counseling and familial risk assessment. This review summarizes current understanding of the molecular basis of mismatch repair deficiency and microsatellite instability in PC, evaluates available diagnostic approaches such as immunohistochemistry, polymerase chain reaction, and next-generation sequencing, and discusses the prognostic and predictive significance of dMMR/MSI-H status. Emerging clinical evidence supporting the use of ICIs in selected patients across neoadjuvant, adjuvant, and advanced disease settings is also reviewed, along with challenges related to assay discordance, tumor heterogeneity, and immunotherapy resistance. Finally, future directions are highlighted, emphasizing the need for standardized testing algorithms, integration of multi-omics and spatial profiling technologies, and prospective clinical studies to optimize precision treatment strategies for this rare but clinically meaningful subtype of pancreatic cancer.
PMID:41563663 | DOI:10.1007/s12094-025-04214-3
-
ScienceDirect Publication: Artificial Intelligence in Medicine
-
BRLA-DDI: A novel framework for drug–drug interaction extraction
Publication date: April 2026Source: Artificial Intelligence in Medicine, Volume 174Author(s): Zhu Yuan, Shuailiang Zhang, Zongjin Li, Huiyun Zhang, Huaqi Zhang, Yaxun Jia
BRLA-DDI: A novel framework for drug–drug interaction extraction
Publication date: April 2026
Source: Artificial Intelligence in Medicine, Volume 174
Author(s): Zhu Yuan, Shuailiang Zhang, Zongjin Li, Huiyun Zhang, Huaqi Zhang, Yaxun Jia
-
MIT Technology Review
-
Everyone wants AI sovereignty. No one can truly have it.
Governments plan to pour $1.3 trillion into AI infrastructure by 2030 to invest in “sovereign AI,” with the premise being that countries should be in control of their own AI capabilities. The funds include financing for domestic data centers, locally trained models, independent supply chains, and national talent pipelines. This is a response to real shocks: covid-era supply chain breakdowns, rising geopolitical tensions, and the war in Ukraine. But the pursuit of absolute autonomy is runnin
Everyone wants AI sovereignty. No one can truly have it.
Governments plan to pour $1.3 trillion into AI infrastructure by 2030 to invest in “sovereign AI,” with the premise being that countries should be in control of their own AI capabilities. The funds include financing for domestic data centers, locally trained models, independent supply chains, and national talent pipelines. This is a response to real shocks: covid-era supply chain breakdowns, rising geopolitical tensions, and the war in Ukraine.
But the pursuit of absolute autonomy is running into reality. AI supply chains are irreducibly global: Chips are designed in the US and manufactured in East Asia; models are trained on data sets drawn from multiple countries; applications are deployed across dozens of jurisdictions.
If sovereignty is to remain meaningful, it must shift from a defensive model of self-reliance to a vision that emphasizes the concept of orchestration, balancing national autonomy with strategic partnership.
Why infrastructure-first strategies hit walls
A November survey by Accenture found that 62% of European organizations are now seeking sovereign AI solutions, driven primarily by geopolitical anxiety rather than technical necessity. That figure rises to 80% in Denmark and 72% in Germany. The European Union has appointed its first Commissioner for Tech Sovereignty.
This year, $475 billion is flowing into AI data centers globally. In the United States, AI data centers accounted for roughly one-fifth of GDP growth in the second quarter of 2025. But the obstacle for other nations hoping to follow suit isn’t just money. It’s energy and physics. Global data center capacity is projected to hit 130 gigawatts by 2030, and for every $1 billion spent on these facilities, $125 million is needed for electricity networks. More than $750 billion in planned investment is already facing grid delays.
And it’s also talent. Researchers and entrepreneurs are mobile, drawn to ecosystems with access to capital, competitive wages, and rapid innovation cycles. Infrastructure alone won’t attract or retain world-class talent.
What works: An orchestrated sovereignty
What nations need isn’t sovereignty through isolation but through specialization and orchestration. This means choosing which capabilities you build, which you pursue through partnership, and where you can genuinely lead in shaping the global AI landscape.
The most successful AI strategies don’t try to replicate Silicon Valley; they identify specific advantages and build partnerships around them.
Singapore offers a model. Rather than seeking to duplicate massive infrastructure, it invested in governance frameworks, digital-identity platforms, and applications of AI in logistics and finance, areas where it can realistically compete.
Israel shows a different path. Its strength lies in a dense network of startups and military-adjacent research institutions delivering outsize influence despite the country’s small size.
South Korea is instructive too. While it has national champions like Samsung and Naver, these firms still partner with Microsoft and Nvidia on infrastructure. That’s deliberate collaboration reflecting strategic oversight, not dependence.
Even China, despite its scale and ambition, cannot secure full-stack autonomy. Its reliance on global research networks and on foreign lithography equipment, such as extreme ultraviolet systems needed to manufacture advanced chips and GPU architectures, shows the limits of techno-nationalism.
The pattern is clear: Nations that specialize and partner strategically can outperform those trying to do everything alone.
Three ways to align ambition with reality
1. Measure added value, not inputs.
Sovereignty isn’t how many petaflops you own. It’s how many lives you improve and how fast the economy grows. Real sovereignty is the ability to innovate in support of national priorities such as productivity, resilience, and sustainability while maintaining freedom to shape governance and standards.
Nations should track the use of AI in health care and monitor how the technology’s adoption correlates with manufacturing productivity, patent citations, and international research collaborations. The goal is to ensure that AI ecosystems generate inclusive and lasting economic and social value.
2. Cultivate a strong AI innovation ecosystem.
Build infrastructure, but also build the ecosystem around it: research institutions, technical education, entrepreneurship support, and public-private talent development. Infrastructure without skilled talent and vibrant networks cannot deliver a lasting competitive advantage.
3. Build global partnerships.
Strategic partnerships enable nations to pool resources, lower infrastructure costs, and access complementary expertise. Singapore’s work with global cloud providers and the EU’s collaborative research programs show how nations advance capabilities faster through partnership than through isolation. Rather than competing to set dominant standards, nations should collaborate on interoperable frameworks for transparency, safety, and accountability.
What’s at stake
Overinvesting in independence fragments markets and slows cross-border innovation, which is the foundation of AI progress. When strategies focus too narrowly on control, they sacrifice the agility needed to compete.
The cost of getting this wrong isn’t just wasted capital—it’s a decade of falling behind. Nations that double down on infrastructure-first strategies risk ending up with expensive data centers running yesterday’s models, while competitors that choose strategic partnerships iterate faster, attract better talent, and shape the standards that matter.
The winners will be those who define sovereignty not as separation, but as participation plus leadership—choosing who they depend on, where they build, and which global rules they shape. Strategic interdependence may feel less satisfying than independence, but it’s real, it is achievable, and it will separate the leaders from the followers over the next decade.
The age of intelligent systems demands intelligent strategies—ones that measure success not by infrastructure owned, but by problems solved. Nations that embrace this shift won’t just participate in the AI economy; they’ll shape it. That’s sovereignty worth pursuing.
Cathy Li is head of the Centre for AI Excellence at the World Economic Forum.
-
Journal of Medical Internet Research
-
Communication Strategies to Promote Patient Engagement in Telemedicine: Systematic Review
Background: The rapid growth of telemedicine offers convenience, flexibility, and accessibility for patients to have health care services worldwide. To succeed in telemedicine, health care practitioners and telemedicine tools must engage patients through effective communication. However, a research gap exists in understanding the communication strategies used in telemedicine and how they effectively engage patients. Objective: This study aims to identify communication strategies influencing pati
Communication Strategies to Promote Patient Engagement in Telemedicine: Systematic Review
-
Omics in Hepatocellular
-
United multi-omics and machine learning refine regulatory T cell-defined hepatocellular carcinoma subtypes
iScience. 2025 Dec 3;29(1):114328. doi: 10.1016/j.isci.2025.114328. eCollection 2026 Jan 16.ABSTRACTHepatocellular carcinoma (HCC) is highly heterogeneous and aggressive, and the absence of precision individual treatment regimen enables repeated immune escape. Exploiting regulatory T cell (Treg) marker genes as key classifiers, we used 10 clustering algorithms to integrate the multi-omics HCC patient data and combined them with 10 machine learning (ML) algorithms to delineate molecular subtypes
United multi-omics and machine learning refine regulatory T cell-defined hepatocellular carcinoma subtypes
iScience. 2025 Dec 3;29(1):114328. doi: 10.1016/j.isci.2025.114328. eCollection 2026 Jan 16.
ABSTRACT
Hepatocellular carcinoma (HCC) is highly heterogeneous and aggressive, and the absence of precision individual treatment regimen enables repeated immune escape. Exploiting regulatory T cell (Treg) marker genes as key classifiers, we used 10 clustering algorithms to integrate the multi-omics HCC patient data and combined them with 10 machine learning (ML) algorithms to delineate molecular subtypes predictive of prognosis and immune response. We identified two cancer subtypes (CSs) that are associated with prognosis, with the second subtype (CS2) showing the most favorable prognostic outcomes. Subsequently, 9 key genes were screened for HCC model scoring, stratifying patients into low-risk (good prognosis, responsive to immunotherapy) and high-risk (poor outcome, not responsive to immunotherapy) groups. The high-risk group may be effective against the mTOR inhibitor AZD8055. Comprehensive multi-omics data and multiple ML algorithms offer key insights into HCC occurrence and evolution, with model scores guiding patient prognosis and treatment clinically.
PMID:41561382 | PMC:PMC12814435 | DOI:10.1016/j.isci.2025.114328
-
cs.AI, q-bio.NC updates on arXiv.org
-
Responsible AI for General-Purpose Systems: Overview, Challenges, and A Path Forward
arXiv:2601.13122v1 Announce Type: new Abstract: Modern general-purpose AI systems made using large language and vision models, are capable of performing a range of tasks like writing text articles, generating and debugging codes, querying databases, and translating from one language to another, which has made them quite popular across industries. However, there are risks like hallucinations, toxicity, and stereotypes in their output that make them untrustworthy. We review various risks and vuln
Responsible AI for General-Purpose Systems: Overview, Challenges, and A Path Forward
-
cs.AI, q-bio.NC updates on arXiv.org
-
Virtual Urbanism: An AI-Driven Framework for Quantifying Urban Identity. A Tokyo-Based Pilot Study Using Diffusion-Generated Synthetic Environments
arXiv:2601.13846v1 Announce Type: new Abstract: This paper introduces Virtual Urbanism (VU), a multimodal AI-driven analytical framework for quantifying urban identity through the medium of synthetic urban replicas. The framework aims to advance computationally tractable urban identity metrics. To demonstrate feasibility, the pilot study Virtual Urbanism and Tokyo Microcosms is presented. A pipeline integrating Stable Diffusion and LoRA models was used to produce synthetic replicas of nine Toky
Virtual Urbanism: An AI-Driven Framework for Quantifying Urban Identity. A Tokyo-Based Pilot Study Using Diffusion-Generated Synthetic Environments
-
cs.AI, q-bio.NC updates on arXiv.org
-
Medication counseling with large language models: balancing flexibility and rigidity
arXiv:2601.11544v1 Announce Type: cross Abstract: The introduction of large language models (LLMs) has greatly enhanced the capabilities of software agents. Instead of relying on rule-based interactions, agents can now interact in flexible ways akin to humans. However, this flexibility quickly becomes a problem in fields where errors can be disastrous, such as in a pharmacy context, but the opposite also holds true; a system that is too inflexible will also lead to errors, as it can become too
Medication counseling with large language models: balancing flexibility and rigidity
-
cs.AI, q-bio.NC updates on arXiv.org
-
DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research
arXiv:2601.11560v1 Announce Type: cross Abstract: Biomedical knowledge graphs (KGs) encode vast, heterogeneous information spanning literature, genes, pathways, drugs, diseases, and clinical trials, but leveraging them collectively for scientific discovery remains difficult. Their structural differences, continual evolution, and limited cross-resource alignment require substantial manual integration, limiting the depth and scale of knowledge exploration. We introduce DeepEvidence, an AI-agent f
DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research
-
cs.AI, q-bio.NC updates on arXiv.org
-
Measuring Stability Beyond Accuracy in Small Open-Source Medical Large Language Models for Pediatric Endocrinology
arXiv:2601.11567v1 Announce Type: cross Abstract: Small open-source medical large language models (LLMs) offer promising opportunities for low-resource deployment and broader accessibility. However, their evaluation is often limited to accuracy on medical multiple choice question (MCQ) benchmarks, and lacks evaluation of consistency, robustness, or reasoning behavior. We use MCQ coupled to human evaluation and clinical review to assess six small open-source medical LLMs (HuatuoGPT-o1 (Chen 2024
Measuring Stability Beyond Accuracy in Small Open-Source Medical Large Language Models for Pediatric Endocrinology
-
cs.AI, q-bio.NC updates on arXiv.org
-
Knowing When to Abstain: Medical LLMs Under Clinical Uncertainty
arXiv:2601.12471v1 Announce Type: cross Abstract: Current evaluation of large language models (LLMs) overwhelmingly prioritizes accuracy; however, in real-world and safety-critical applications, the ability to abstain when uncertain is equally vital for trustworthy deployment. We introduce MedAbstain, a unified benchmark and evaluation protocol for abstention in medical multiple-choice question answering (MCQA) -- a discrete-choice setting that generalizes to agentic action selection -- integra
Knowing When to Abstain: Medical LLMs Under Clinical Uncertainty
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Cloud-based Multi-Agentic Workflow for Science
arXiv:2601.12607v1 Announce Type: cross Abstract: As Large Language Models (LLMs) become ubiquitous across various scientific domains, their lack of ability to perform complex tasks like running simulations or to make complex decisions limits their utility. LLM-based agents bridge this gap due to their ability to call external resources and tools and thus are now rapidly gaining popularity. However, coming up with a workflow that can balance the models, cloud providers, and external resources i
A Cloud-based Multi-Agentic Workflow for Science
-
cs.AI, q-bio.NC updates on arXiv.org
-
SciHorizon-GENE: Benchmarking LLM for Life Sciences Inference from Gene Knowledge to Functional Understanding
arXiv:2601.12805v1 Announce Type: cross Abstract: Large language models (LLMs) have shown growing promise in biomedical research, particularly for knowledge-driven interpretation tasks. However, their ability to reliably reason from gene-level knowledge to functional understanding, However, their ability to reliably reason from gene-level knowledge to functional understanding, a core requirement for knowledge-enhanced cell atlas interpretation, remains largely underexplored. To address this gap
SciHorizon-GENE: Benchmarking LLM for Life Sciences Inference from Gene Knowledge to Functional Understanding
-
cs.AI, q-bio.NC updates on arXiv.org
-
SciCoQA: Quality Assurance for Scientific Paper--Code Alignment
arXiv:2601.12910v1 Announce Type: cross Abstract: We present SciCoQA, a dataset for detecting discrepancies between scientific publications and their codebases to ensure faithful implementations. We construct SciCoQA from GitHub issues and reproducibility papers, and to scale our dataset, we propose a synthetic data generation method for constructing paper-code discrepancies. We analyze the paper-code discrepancies in detail and propose discrepancy types and categories to better understand the
SciCoQA: Quality Assurance for Scientific Paper--Code Alignment
-
cs.AI, q-bio.NC updates on arXiv.org
-
AI-generated data contamination erodes pathological variability and diagnostic reliability
arXiv:2601.12946v1 Announce Type: cross Abstract: Generative artificial intelligence (AI) is rapidly populating medical records with synthetic content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological varia
AI-generated data contamination erodes pathological variability and diagnostic reliability
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-objective fluorescent molecule design with a data-physics dual-driven generative framework
arXiv:2601.13564v1 Announce Type: cross Abstract: Designing fluorescent small molecules with tailored optical and physicochemical properties requires navigating vast, underexplored chemical space while satisfying multiple objectives and constraints. Conventional generate-score-screen approaches become impractical under such realistic design specifications, owing to their low search efficiency, unreliable generalizability of machine-learning prediction, and the prohibitive cost of quantum chemic
Multi-objective fluorescent molecule design with a data-physics dual-driven generative framework
-
cs.AI, q-bio.NC updates on arXiv.org
-
Neural Organ Transplantation (NOT): Checkpoint-Based Modular Adaptation for Transformer Models
arXiv:2601.13580v1 Announce Type: cross Abstract: We introduce Neural Organ Transplantation (NOT), a modular adaptation framework that enables trained transformer layers to function as reusable transferable checkpoints for domain adaptation. Unlike conventional fine-tuning approaches that tightly couple trained parameters to specific model instances and training data, NOT extracts contiguous layer subsets ("donor organs") from pre-trained models, trains them independently on domain-specific dat